Aclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting

WAYNE, Pa., May 15, 2018 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, has provided an unrestricted educational grant for the

Aclaris Therapeutics to Present at the 2018 American Hair Research Summit

WAYNE, Pa., May 11, 2018 (GLOBE NEWSWIRE) — Paul Changelian, Ph.D., Vice President, Biology, Aclaris Therapeutics, Inc. (NASDAQ:ACRS), will speak at the 2018 American Hair Research Summit on “Preclinical to Clinical Translation of JAK Kinase Inhibitors” on May 15. The meeting is organized by the American Hair

Aclaris Therapeutics to Attend Upcoming Investor Conferences

WAYNE, Pa., May 10, 2018 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced that management will attend the following

Aclaris Therapeutics Announces Availability of ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w)

ESKATA™ is the First and Only FDA-Approved Topical Treatment for Raised Seborrheic Keratoses; Aclaris Partnering with McKesson for U.S. Distribution WAYNE, Pa., May 07, 2018 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that ESKATA™ is now available for